Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Industry News
Organon announces Research Collaboration in China
11/21/2005
Organon has announced an important research collaboration with HD Biosciences, one of the leading biotech companies in China.
OSS, the Netherlands, Nov. 18, 2005 - Akzo Nobel's human healthcare business, Organon, has announced an important research collaboration with HD Biosciences, one of the leading biotech companies in China.
The agreement relates to the development by Shanghai-based HD Biosciences of functional assays for a number of identified G-protein coupled receptors and ion channels. The project will start with a total of five molecular targets identified by Organon.
“China is an increasingly important pharmaceutical market,” said Dr David Nicholson, Organon’s Executive Vice President of Global Research. “The growing scientific expertise, as well as the history of traditional Chinese medicine, makes research collaborations in this country attractive.”
He went on: “Organon is in the process of setting up early discovery agreements with Chinese partners to forge closer links with the country’s highly skilled and motivated scientists. This agreement with HD Biosciences is the first research collaboration with a Chinese biotech partner that we have finalized.”
Under the terms of the contract, HD Biosciences will develop functional assays for high-throughput screening. All targets have been selected on the basis of their potential as starting points for the discovery of innovative new treatments for disorders of the central nervous system.
“HD Biosciences’ mission is to provide advanced solutions for drug discovery and assist pharmaceutical and biotech companies in their search for innovative, effective, and safe drug candidates at a controlled cost,” added Dr Xuehai Tan, President of HD Biosciences.
“As such, we are delighted to be working with Organon on this project and look forward to a successful and collaborative partnership.”
Relate News
more
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit